JP2020534373A5 - - Google Patents

Download PDF

Info

Publication number
JP2020534373A5
JP2020534373A5 JP2020538750A JP2020538750A JP2020534373A5 JP 2020534373 A5 JP2020534373 A5 JP 2020534373A5 JP 2020538750 A JP2020538750 A JP 2020538750A JP 2020538750 A JP2020538750 A JP 2020538750A JP 2020534373 A5 JP2020534373 A5 JP 2020534373A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutically acceptable
acceptable salt
compound
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020538750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534373A (ja
JP7394768B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052047 external-priority patent/WO2019060611A1/en
Publication of JP2020534373A publication Critical patent/JP2020534373A/ja
Publication of JP2020534373A5 publication Critical patent/JP2020534373A5/ja
Application granted granted Critical
Publication of JP7394768B2 publication Critical patent/JP7394768B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020538750A 2017-09-20 2018-09-20 キナーゼ阻害剤としての環状イミノピリミジン誘導体 Active JP7394768B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762561142P 2017-09-20 2017-09-20
US62/561,142 2017-09-20
PCT/US2018/052047 WO2019060611A1 (en) 2017-09-20 2018-09-20 CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES

Publications (3)

Publication Number Publication Date
JP2020534373A JP2020534373A (ja) 2020-11-26
JP2020534373A5 true JP2020534373A5 (enExample) 2021-11-04
JP7394768B2 JP7394768B2 (ja) 2023-12-08

Family

ID=64457074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020538750A Active JP7394768B2 (ja) 2017-09-20 2018-09-20 キナーゼ阻害剤としての環状イミノピリミジン誘導体

Country Status (10)

Country Link
US (2) US11254680B2 (enExample)
EP (1) EP3684772B1 (enExample)
JP (1) JP7394768B2 (enExample)
KR (1) KR102796209B1 (enExample)
CN (1) CN111247152B (enExample)
AU (1) AU2018338098B2 (enExample)
BR (1) BR112020005455A2 (enExample)
CA (1) CA3076202A1 (enExample)
MX (1) MX2020003126A (enExample)
WO (1) WO2019060611A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102796209B1 (ko) * 2017-09-20 2025-04-16 에이비엠 쎄라퓨틱스 코포레이션 키나아제 억제제로서의 시클릭 이미노피리미딘 유도체
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和失調症之化合物
ES3018143T3 (en) * 2019-12-10 2025-05-14 Hoffmann La Roche New braf inhibitors as paradox breakers
WO2021250521A1 (en) 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
MX2023001312A (es) * 2020-08-07 2023-04-12 Abm Therapeutics Corp Inhibidores de quinasa y usos de los mismos.
CN114380697A (zh) * 2021-11-30 2022-04-22 上海毕得医药科技股份有限公司 一种n-甲基乙基胺盐酸盐的制备工艺
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
CN117209503B (zh) * 2023-09-13 2025-10-17 苏州翔实医药发展有限公司 一种5,6-二氢咪唑并[1,2-c]喹唑啉及其衍生物合成的方法
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
WO2025153057A1 (zh) * 2024-01-17 2025-07-24 海思科医药集团股份有限公司 一种含braf抑制剂的药物组合物及其在医药上的应用
WO2025176185A1 (zh) * 2024-02-23 2025-08-28 海思科医药集团股份有限公司 一种braf抑制剂的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE411996T1 (de) * 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
US20100216779A1 (en) 2007-06-01 2010-08-26 Glaxosmithkline Llc Imidazopyridine Kinase Inhibitors
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
RU2550038C2 (ru) 2010-12-02 2015-05-10 Медпакто Инк. Новое производное пуринилпиридиниламино-2,4-дифторфенилсульфонамида, его фармацевтически приемлемая соль, способ его получения и фармацевтическая композиция, обладающая ингибирующей активностью в отношении raf-киназы, содержащая данное соединение в качестве активного ингредиента
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
BR112015005562A2 (pt) * 2012-09-14 2017-08-08 Eternity Bioscience Inc compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase.
WO2014047648A1 (en) 2012-09-24 2014-03-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9321762B2 (en) 2013-12-11 2016-04-26 Development Center For Biotechnology Quinazoline compounds, method for preparing the same and use thereof
CN105272970A (zh) 2014-07-03 2016-01-27 中国药科大学 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途
JP6826526B6 (ja) 2014-07-16 2021-03-31 ディベロップメント センター フォー バイオテクノロジーDevelopment Center For Biotechnology キノキサリン化合物、それを調製する方法およびその使用
KR102796209B1 (ko) * 2017-09-20 2025-04-16 에이비엠 쎄라퓨틱스 코포레이션 키나아제 억제제로서의 시클릭 이미노피리미딘 유도체

Similar Documents

Publication Publication Date Title
JP2020534373A5 (enExample)
KR102796209B1 (ko) 키나아제 억제제로서의 시클릭 이미노피리미딘 유도체
KR102008635B1 (ko) 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
JP6866967B2 (ja) サイクリン依存性キナーゼcdk9の新規阻害剤
KR100737090B1 (ko) 축합 이미다졸륨 유도체
JP2019527682A5 (enExample)
CA3019450A1 (en) Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
JP2010539095A5 (enExample)
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
RU2012103487A (ru) Ингибирующие jak соединения на основе пиразолопиримидина и способы
BR112012018415A2 (pt) composto, composição, métodos de preparar uma composição e de tratamento, e, uso de um composto.
JP2020518672A (ja) キナーゼ阻害活性を有する化合物、その製造方法及び用途
TW201917126A (zh) 二氫二酮
JP2020527173A5 (enExample)
JP2022037004A (ja) 癌の治療に有用なparp1、parp2、および/またはチューブリンの阻害剤としてのフタラジン誘導体
US20240287048A1 (en) Substituted acyl sulfonamides for treating cancer
JP2017137323A (ja) 新規抗がん剤
JP2017502069A (ja) 有機化合物
BR112016017628A2 (pt) compostos de quinazolinona deuterados e composições farmacêuticas que compreendem os mesmos
BR112021013345A2 (pt) Compostos de 1,2,4-triazin-3(2h)-ona para o tratamento de doenças hiperproliferativas
CN106045973B (zh) 4-酰胺基苯并咪唑吖啶类化合物及其制备方法和用途
JP2006506319A5 (enExample)
JP2021512894A (ja) 治療用化合物および組成物
PL231063B1 (pl) Pochodne 1-(podstawionej sulfonylo)-2-aminoimidazoliny jako środki przeciwnowotworowe
US9321766B1 (en) Kinase inhibitors